Status:
COMPLETED
AZD5438 in Patients With Advanced Solid Malignancies
Lead Sponsor:
AstraZeneca
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data fro...
Eligibility Criteria
Inclusion
- Advanced solid malignancy
- Cancer refractory to standard treatments or for which no standard therapy exits
Exclusion
- Radiotherapy within 3 weeks of the start of treatment
- Investigational product within the last 3 weeks
- Systemic cytotoxic anti-cancer therapy within the last 3 weeks
- Any significant clinical disorder that makes it undesirable for the patient to participate
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00088790
Start Date
July 1 2004
End Date
December 1 2005
Last Update
January 26 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Boston, Massachusetts, United States
2
Research Site
New York, New York, United States